{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:54:17Z","timestamp":1781639657685,"version":"3.54.5"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Pancreatic cancer poses a significant clinical challenge due to its aggressive nature and poor prognosis. While surgery remains the primary curative option, the emergence of immunotherapy presents a promising avenue for improving patient outcomes. This systematic review evaluates the effectiveness and safety of perioperative immunotherapy in patients with pancreatic cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, Cochrane Library, and clinicaltrials.gov were searched for all relevant articles published up to July 2024. Only randomized controlled trials (RCTs) were included, and the PRISMA guidelines were followed. The primary outcome was overall survival (OS); secondary outcomes included progression-free survival (PFS), recurrence-free survival (RFS), disease-free survival (DFS), adverse events, and immune activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of six RCTs were included in this review. Among the six included trials, three reported significant improvements in OS with perioperative immunotherapy. PFS was improved in three studies, while RFS and DFS showed mixed results; only one trial reported a significant improvement in DFS. Safety outcomes varied across studies, with one study reporting Grade\u2009\u2265\u20093 adverse events related to immunotherapy, while two studies found that the side effects were comparable between the two groups. Notably, four studies observed increased immune activity, marked by higher lymphocyte counts and enhanced activity of tumor-infiltrating lymphocytes in the immunotherapy group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Perioperative immunotherapy appears to be a feasible and potentially beneficial approach in pancreatic cancer, showing promise in improving survival and immune responsiveness. While findings are heterogeneous, these results support further investigation through large-scale, biomarker-driven studies to optimize its integration into perioperative management strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12029-026-01431-z","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T02:44:33Z","timestamp":1772505873000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Perioperative Immunotherapy for Pancreatic Cancer: A Systematic Review of Randomized Controlled Trials"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9855-7961","authenticated-orcid":false,"given":"Tanzeela Sameen","family":"Saeed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5218-5479","authenticated-orcid":false,"given":"Muhammad Ramish","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Shoaib","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5949-2634","authenticated-orcid":false,"given":"Nihal","family":"Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8927-0127","authenticated-orcid":false,"given":"Uswa","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5212-7568","authenticated-orcid":false,"given":"Sama","family":"Mehtab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2859-4249","authenticated-orcid":false,"given":"Muhammad Fahad","family":"Abdullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirza Farhana","family":"Iqbal Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armeen","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2228-7991","authenticated-orcid":false,"given":"Khizar","family":"Razzaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Asif","family":"Maqbool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"1431_CR1","unstructured":"Annual Cancer Facts &. Figures | American Cancer Society [Internet]. [cited 2024 Nov 17]. Available from: https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures.html"},{"key":"1431_CR2","unstructured":"Estimated Projection of US Cancer Incidence and Death. to 2040 | Oncology | JAMA Network Open | JAMA Network [Internet]. [cited 2024 Nov 17]. Available from: https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2778204"},{"issue":"6","key":"1431_CR3","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.3390\/curroncol31060250","volume":"31","author":"M Domaga\u0142a-Haduch","year":"2024","unstructured":"Domaga\u0142a-Haduch M, Gorzelak-Magiera A, Michalecki \u0141, Gisterek-Grocholska I. Radiochemotherapy in pancreatic cancer. Curr Oncol. 2024;31(6):3291\u2013300.","journal-title":"Curr Oncol"},{"issue":"1","key":"1431_CR4","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3748\/wjg.v21.i1.262","volume":"21","author":"T Yamamoto","year":"2015","unstructured":"Yamamoto T, et al. Long-term survival after resection of pancreatic cancer: a single-center retrospective analysis. World J Gastroenterol WJG. 2015;21(1):262.","journal-title":"World J Gastroenterol WJG"},{"key":"1431_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/8282391","volume":"2017","author":"J Chen","year":"2017","unstructured":"Chen J, Xiao-Zhong G, Qi X-S. Clinical Outcomes of Specific Immunotherapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. J Immunol Res. 2017;2017:1\u201316. https:\/\/doi.org\/10.1155\/2017\/8282391.","journal-title":"J Immunol Res"},{"issue":"5","key":"1431_CR6","doi-asserted-by":"publisher","first-page":"e373","DOI":"10.3747\/co.25.3840","volume":"25","author":"NA Nixon","year":"2018","unstructured":"Nixon NA, et al. Current landscape of immunotherapy in the treatment of solid tumours, with future opportunities and challenges. Curr Oncol. 2018;25(5):e373.","journal-title":"Curr Oncol"},{"issue":"6","key":"1431_CR7","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.ccell.2020.08.004","volume":"38","author":"AS Bear","year":"2020","unstructured":"Bear AS, Vonderheide RH, O\u2019Hara MH. Challenges and opportunities for pancreatic cancer immunotherapy. Cancer Cell. 2020;38(6):788\u2013802.","journal-title":"Cancer Cell"},{"issue":"15","key":"1431_CR8","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.3390\/cancers15153967","volume":"15","author":"RC Chick","year":"2023","unstructured":"Chick RC, Gunderson AJ, Rahman S, Cloyd JM. Neoadjuvant immunotherapy for localized pancreatic cancer: challenges and early results. Cancers. 2023;15(15):3967.","journal-title":"Cancers"},{"issue":"4","key":"1431_CR9","doi-asserted-by":"publisher","first-page":"534","DOI":"10.21037\/hbsn-21-238","volume":"10","author":"C Springfeld","year":"2021","unstructured":"Springfeld C, Bailey P, Hackert T, Neoptolemos JP. Perioperative immunotherapy for pancreatic cancer is on its way. Hepatobiliary Surg Nutr. 2021;10(4):534.","journal-title":"Hepatobiliary Surg Nutr"},{"key":"1431_CR10","doi-asserted-by":"crossref","unstructured":"Page MJ et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews, bmj, vol. 372, 2021, Accessed: Jul. 14, 2025. [Online]. Available: https:\/\/www.bmj.com\/content\/372\/bmj.n71.short","DOI":"10.1136\/bmj.n71"},{"key":"1431_CR11","unstructured":"Sterne JA et al. RoB 2: a revised tool for assessing risk of bias in randomised trials, bmj, vol. 366, 2019, Accessed: Jul. 14, 2025. [Online]. Available: https:\/\/www.bmj.com\/content\/366\/bmj.l4898.short"},{"issue":"3B","key":"1431_CR12","first-page":"1951","volume":"28","author":"R Caprotti","year":"2008","unstructured":"Caprotti R, et al. Free-from-progression period and overall short preoperative immunotherapy with IL-2 increases the survival of pancreatic cancer patients treated with macroscopically radical surgery. Anticancer Res. 2008;28(3B):1951\u20134.","journal-title":"Anticancer Res"},{"issue":"12","key":"1431_CR13","doi-asserted-by":"publisher","first-page":"e007586","DOI":"10.1136\/jitc-2023-007586","volume":"11","author":"MH Katz","year":"2023","unstructured":"Katz MH, et al. Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma. J Immunother Cancer. 2023;11(12):e007586.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1431_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1046\/j.1365-2168.2000.01336.x","volume":"87","author":"M Kobari","year":"2000","unstructured":"Kobari M, Egawa S, Shibuya K, Sunamura M, Saitoh K, Matsuno S Effect of intraportal adoptive immunotherapy on liver metastases after resection of pancreatic cancer. J Br Surg Jan. 2000;87(1):43\u20138. . https:\/\/doi.org\/10.1046\/j.1365-2168.2000.01336.x.","journal-title":"J Br Surg Jan."},{"issue":"6","key":"1431_CR15","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1097\/00000658-200212000-00013","volume":"236","author":"NJ Lygidakis","year":"2002","unstructured":"Lygidakis NJ, Sgourakis G, Georgia D, Vlachos L, Raptis S. Regional targeting chemoimmunotherapy in patients undergoing pancreatic resection in an advanced stage of their disease: a prospective randomized study. Ann Surg. 2002;236(6):806\u201313.","journal-title":"Ann Surg"},{"issue":"1","key":"1431_CR16","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1089\/pancan.2020.0021","volume":"7","author":"P Muscarella","year":"2021","unstructured":"Muscarella P, Mar A, Phase, et al. 2 Randomized Placebo-Controlled Adjuvant Trial of GI-4000, a Recombinant Yeast Expressing Mutated RAS Proteins in Patients with Resected Pancreas Cancer. J Pancreat Cancer. 2021;7(1):8\u201319. . https:\/\/doi.org\/10.1089\/pancan.2020.0021","journal-title":"J Pancreat Cancer."},{"key":"1431_CR17","doi-asserted-by":"crossref","unstructured":"Zhu X et al. Effect of stereotactic body radiotherapy dose escalation plus pembrolizumab and trametinib versus stereotactic body radiotherapy dose escalation plus gemcitabine for locally recurrent pancreatic cancer after surgical resection on survival outcomes: A secondary analysis of an open-label, randomised, controlled, phase 2 trial, EClinicalMedicine, vol. 55, 2023, Accessed: Jul. 14, 2025. [Online]. Available: https:\/\/www.thelancet.com\/journals\/eclinm\/article\/PIIS2589-5370(22)00493-X\/fulltext","DOI":"10.1016\/j.eclinm.2022.101764"},{"issue":"25","key":"1431_CR18","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/nejm198812223192527","volume":"319","author":"SA Rosenberg","year":"1988","unstructured":"Rosenberg SA, et al. Dec., Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma. N Engl J Med. 1988;319(25):1676\u201380. . https:\/\/doi.org\/10.1056\/nejm198812223192527","journal-title":"N Engl J Med."},{"issue":"5","key":"1431_CR19","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.coi.2011.08.003","volume":"23","author":"W Liao","year":"2011","unstructured":"Liao W, Lin J-X, Leonard WJ. IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Curr Opin Immunol. 2011;23(5):598\u2013604.","journal-title":"Curr Opin Immunol"},{"issue":"8","key":"1431_CR20","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","volume":"33","author":"RE Royal","year":"2010","unstructured":"Royal RE, et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010;33(8):828\u201333.","journal-title":"J Immunother"},{"key":"1431_CR21","doi-asserted-by":"publisher","unstructured":"Le DT, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. Jul. 2017;357(6349):409\u201313. https:\/\/doi.org\/10.1126\/science.aan6733.","DOI":"10.1126\/science.aan6733"},{"issue":"7","key":"1431_CR22","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1053\/j.gastro.2018.12.038","volume":"156","author":"VP Balachandran","year":"2019","unstructured":"Balachandran VP, Beatty GL, Dougan SK. Broadening the impact of immunotherapy to pancreatic cancer: challenges and opportunities. Gastroenterology. 2019;156(7):2056\u201372.","journal-title":"Gastroenterology"},{"issue":"16","key":"1431_CR23","doi-asserted-by":"publisher","first-page":"4266","DOI":"10.1158\/1078-0432.CCR-11-3114","volume":"18","author":"C Feig","year":"2012","unstructured":"Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The pancreas cancer microenvironment. Clin Cancer Res. 2012;18(16):4266\u201376.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1431_CR24","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.trecan.2018.04.001","volume":"4","author":"AH Morrison","year":"2018","unstructured":"Morrison AH, Byrne KT, Vonderheide RH. Immunotherapy and prevention of pancreatic cancer. Trends Cancer. 2018;4(6):418\u201328.","journal-title":"Trends Cancer"},{"issue":"7547","key":"1431_CR25","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature14292","volume":"520","author":"C Twyman-Saint","year":"2015","unstructured":"Twyman-Saint C, Victor, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520(7547):373\u20137.","journal-title":"Nature"},{"issue":"3","key":"1431_CR26","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ccell.2015.08.004","volume":"28","author":"R Dahan","year":"2015","unstructured":"Dahan R, Sega E, Engelhardt J, Selby M, Korman AJ, Ravetch JV. Fc\u03b3Rs modulate the anti-tumor activity of antibodies targeting the PD-1\/PD-L1 axis. Cancer Cell. 2015;28(3):285\u201395.","journal-title":"Cancer Cell"},{"issue":"4","key":"1431_CR27","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1097\/SLA.0000000000002957","volume":"268","author":"S Tsai","year":"2018","unstructured":"Tsai S, Christians KK, George B, Ritch PS, Dua K, Khan A, Mackinnon AC, Tolat P, Ahmad SA, Hall WA, Erickson BA. A phase II clinical trial of molecular profiled neoadjuvant therapy for localized pancreatic ductal adenocarcinoma. Ann Surg. 2018;268(4):610\u20139.","journal-title":"Ann Surg"},{"issue":"7963","key":"1431_CR28","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, Lihm J, Ceglia N, Guasp P, Chu A, Yu R. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618(7963):144\u201350.","journal-title":"Nature"},{"issue":"8","key":"1431_CR29","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00262-025-04096-y","volume":"74","author":"NU Deshpande","year":"2025","unstructured":"Deshpande NU, Bianchi A, Amirian H, De Castro Silva I, Rafie CI, Surnar B, Rajkumar K, Ashokan A, Ogobuiro IC, Patel M, Stelekati E. Cell-specific nanoengineering strategy to disrupt tolerogenic signaling from myeloid-derived suppressor cells and invigorate antitumor immunity in pancreatic cancer. Cancer Immunol Immunother. 2025;74(8):247.","journal-title":"Cancer Immunol Immunother."},{"key":"1431_CR30","doi-asserted-by":"publisher","unstructured":"Conroy T, et al. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. N Engl J Med. May 2011;364:1817\u201325. https:\/\/doi.org\/10.1056\/nejmoa1011923.","DOI":"10.1056\/nejmoa1011923"},{"issue":"18","key":"1431_CR31","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/nejmoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, et al. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine. N Engl J Med. 2013;369(18):1691\u2013703. . https:\/\/doi.org\/10.1056\/nejmoa1304369","journal-title":"N Engl J Med"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01431-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01431-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01431-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:15:23Z","timestamp":1781637323000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01431-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1431"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01431-z","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"assertion":[{"value":"22 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"56"}}